Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
66 hedge funds and large institutions have $178M invested in Poseida Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 17 closing their positions.
85% more call options, than puts
Call options by funds: $24K | Put options by funds: $13K
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
2% more funds holding
Funds holding: 65 → 66 (+1)
0.03% less ownership
Funds ownership: 41.95% → 41.92% (-0.03%)
6% less capital invested
Capital invested by funds: $191M → $178M (-$12.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Natixis
Paris,
France
|
+$11.6M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.6M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$776K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$663K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$577K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$5.74M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.51M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$2.2M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.11M |
| 5 |
MA
MCF Advisors
Covington,
Kentucky
|
-$482K |
PSTX Hedge Fund Activity: Q4 2021 in Review
66 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q4 2021, worth a combined $178M — down 6.4% from $191M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PSTX positions and 17 closed out — a net gain of 3 holders — while 18 added to existing stakes and 16 trimmed.
The largest buyer was Natixis, opening a new position worth an estimated $11.6M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $5.74M sold.
- 66 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q4 2021, up from 65 in Q3 2021.
- Funds reported $178M of Poseida Therapeutics, Inc. Common Stock stock for Q4 2021, down 6.4% quarter-over-quarter.
- 20 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q4 2021 and 17 closed out, a net change of +3 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q4 2021 was Natixis, an estimated $11.6M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q4 2021 was Perceptive Advisors, an estimated $5.74M sold.
Based on aggregated 13F filings for Q4 2021.